A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 19 Jun 2017 Planned number of patients changed from 270 to 470.
- 30 May 2017 Planned End Date changed from 1 Jun 2021 to 8 Jul 2021.
- 30 May 2017 Planned primary completion date changed from 1 Jun 2021 to 8 Jul 2021.